Application
Quantification of Eculizumab
Specific labelling
Arginine: 13C6,15N4>99%
Lysine: 13C6,15N2, >99%
Description
Labelled Eculizumab is a recombinant, stable isotope labelled monoclonal IgG2-G4-Kappadesignedforuseasaninternal standard for quantitative analysis of Eculizumab in plasma samples. Eculizumab targets complement protein C5 and is used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
This product is for research use only and is not intended for diagnostic or therapeutic use.
For any quantities, please contact us
Custom clearance and freight insurance costs to be borne by the customer.
This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only. Information about licenses for other uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powdermill Rd.; Wilmington, DE 19803; 1-877-881-9787 (voice), 1-302-695-1437 (fax), licensing@dupont.com.
